EGFR and neoplasm: For example, EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, are approved for patients with mutations in the EGFR gene; it is now widely accepted that response to EGFR TKIs is greater in patients with tumours harbouring EGFR mutations compared with wild-type EGFR oncogenes [15].